Jason B Ibarra

US Patent:

20020143182, Oct 3, 2002

Filed:

Mar 7, 2002

Appl. No.:

10/094142

Inventors:

Magnus Pfahl - Solana Beach CA, US
Catherine Tachdjian - San Diego CA, US
Hussien Al-Shamma - Encinitas CA, US
Andrea Fanjul - San Diego CA, US
David Pleynet - San Diego CA, US
Lyle Spruce - Chula Vista CA, US
Torsten Wiemann - Cardiff By The Sea CA, US
Jason Ibarra - Imperial Beach CA, US

International Classification:

C07F007/02
C 07D 4 3/02

US Classification:

546/014000, 546/268400, 546/272400, 546/272700

Abstract:

The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): wherein: (a) m is an integer 0 or 1; (b) Ris an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Aris an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Aris an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) Ris hydrogen, hydroxy, alkyl or substituted alkyl; (f) - - - - - represents a bond present or absent; and (g) W, X, Y and Z are independently or together C(O)—, C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.

US Patent:

20080119477, May 22, 2008

Filed:

Dec 9, 2005

Appl. No.:

11/792894

Inventors:

Brian M. Smith - San Diego CA, US
Vincent J. Santora - Carlsbad CA, US
Rena Hayashi - San Diego CA, US
Jason B. Ibarra - Las Vegas NV, US
Jeffrey A. Schultz - San Diego CA, US
Scott A. Estrada - La Jolla CA, US

International Classification:

A61K 31/496
A61K 31/495
C07D 409/02
C07D 403/02
C07D 405/02

US Classification:

51425213, 51425503, 51425301, 5142541, 544360, 544372, 544390

Abstract:

The present invention relates to certain biarylz and arylheteroaryl piperazine derivatives of Formula (Ia) that are modulators of the 5HTreceptor. Accordingly, compounds of the present invention are useful for the treatment of 5HTreceptor associated diseases or disorders, such as, obesity, Alzheimer Disease, erectile dysfunction and related disorders.

US Patent:

20080255137, Oct 16, 2008

Filed:

Dec 9, 2005

Appl. No.:

11/792742

Inventors:

Brian M Smith - San Diego CA, US
Vincent J. Santora - Carlsbad CA, US
Rena Hayashi - San Diego CA, US
Jason B. Ibarra - Las Vegas NV, US
Jeffrey A. Schultz - San Diego CA, US
Scott A. Estrada - La Jolla CA, US

Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/496
C07D 409/10
C07D 401/10
C07D 405/10
C07D 241/04
A61P 3/00
A61P 25/00

US Classification:

51425213, 544379, 544360, 51425301, 5142541, 544403, 51425503

Abstract:

The present invention relates to certain N-biaryl and N-arylheteroaryl 2-substituted piperazine derivatives of Formula (Ia) that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the treatment of 5HT2C receptor associated diseases or disorders, such as, obesity, Alzheimer Disease, erectile dysfunction and related disorders.

US Patent:

20110224262, Sep 15, 2011

Filed:

Nov 24, 2009

Appl. No.:

13/131203

Inventors:

Thuy-Anh Tran - San Diego CA, US
Jason B. Ibarra - Las Vegas NV, US
Young-Jun Shin - San Diego CA, US
Brett Ullman - San Diego CA, US
Ning Zou - San Diego CA, US
Xi Zeng - San Diego CA, US

Assignee:

ARENA PHARMACEUTICALS, INC. - San Diego CA

International Classification:

A61K 31/4439
C07D 231/54
A61K 31/416
C07D 231/10
A61K 31/415
C07D 401/04
C07D 405/04
C07D 409/04
A61K 31/4155
A61P 9/00
A61P 7/02
A61P 11/06
A61P 3/10
A61P 27/06
A61P 27/02
A61P 29/00
A61P 17/06
A61P 9/12
A61P 19/02
A61P 41/00
A61P 21/00
A61P 1/00

US Classification:

514341, 5483591, 5483761, 514406, 5462754, 5483657

Abstract:

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

US Patent:

20110245251, Oct 6, 2011

Filed:

Dec 7, 2009

Appl. No.:

13/133036

Inventors:

Thuy-Anh Tran - San Diego CA, US
Rena Hayashi - Hacienda Heights CA, US
Jason B. Ibarra - Las Vegas NV, US
Brett Ullman - San Diego CA, US
Ning Zou - San Diego CA, US

Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/53
C07D 237/14
C07D 401/04
C07D 409/04
C07D 403/04
C07D 253/07
A61K 31/50
A61K 31/501
C12N 5/071
A61P 9/12
A61P 7/02
A61P 9/00
A61P 9/10
A61P 11/06
A61P 3/10
A61P 13/12
A61P 27/02
A61P 25/02
A61P 27/06
A61P 29/00
A61P 17/06
A61P 19/02
A61P 37/06
A61P 25/28
A61P 17/10
A61P 11/00

US Classification:

514242, 544239, 544238, 544182, 514247, 51425203, 51425205, 51425201, 435375

Abstract:

Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

US Patent:

20200392123, Dec 17, 2020

Filed:

Apr 30, 2020

Appl. No.:

16/863625

Inventors:

- San Diego CA, US
Jason B. IBARRA - Las Vegas NV, US
Young-Jun SHIN - San Diego CA, US
Brett ULLMAN - San Diego CA, US
Ning ZOU - San Diego CA, US
Xi ZENG - San Diego CA, US

International Classification:

C07D 409/04
C07D 231/12
C07D 231/54
C07D 231/56
C07D 401/04
C07D 405/04
A61P 11/00
A61P 9/00
C07D 231/18

Abstract:

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

US Patent:

20200385357, Dec 10, 2020

Filed:

Aug 25, 2020

Appl. No.:

17/002603

Inventors:

- San Diego CA, US
Rena HAYASHI - Hacienda Heights CA, US
Jason B. IBARRA - Las Vegas NV, US
Brett ULLMAN - San Diego CA, US
Ning ZOU - San Diego CA, US

International Classification:

C07D 237/14
C07D 253/07
C07D 401/04
C07D 403/04
C07D 409/04

Abstract:

Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

US Patent:

20190270731, Sep 5, 2019

Filed:

Nov 6, 2018

Appl. No.:

16/181457

Inventors:

- San Diego CA, US
Jason B. Ibarra - Las Vegas NV, US
Young-Jun Shin - San Diego CA, US
Brett Ullman - San Diego CA, US
Ning Zou - San Diego CA, US
Xi Zeng - San Diego CA, US

International Classification:

C07D 409/04
A61P 9/00
A61P 11/00
C07D 405/04
C07D 231/12
C07D 231/56
C07D 231/54
C07D 231/18
C07D 401/04

Abstract:

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).